1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,540 | 1,650 | 10:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | BOAN BIOTECH (06955): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025 | - | HKEx | ||
| 15.08. | BOAN BIOTECH (06955): NOTICE OF BOARD MEETING | - | HKEx | ||
| 14.08. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 14.08. | BOAN BIOTECH (06955): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| SHANDONG BOAN BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 08.08. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT DULAGLUTIDE INJECTION (BOYOUPING) APPROVED FOR MARKETING IN CHINA | 3 | HKEx | ||
| 07.08. | BOAN BIOTECH (06955): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 4 | HKEx | ||
| 23.06. | BOAN BIOTECH (06955): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 23.06. | BOAN BIOTECH (06955): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.06. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR BA1302 IN THE U.S. | 1 | HKEx | ||
| 11.06. | BOAN BIOTECH (06955): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 11.06. | BOAN BIOTECH (06955): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2025, APPOINTMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR, CHANGES ... | - | HKEx | ||
| 05.06. | BOAN BIOTECH (06955): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 04.06. | BOAN BIOTECH (06955): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 5 JUNE 2025 (APPLICABLE TO HOLDERS OF H SHARES) | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): (1) 2024 REPORT OF THE BOARD OF DIRECTORS (2) 2024 REPORT OF THE BOARD OF SUPERVISORS (3) 2024 ANNUAL REPORT (4) PROPOSED APPOINTMENT ... | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | BOAN BIOTECH (06955): ANNUAL REPORT 2024 | - | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | 0,00 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| APOGEE THERAPEUTICS | 36,860 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| IMMUNOVANT | 15,530 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| ARCELLX | 75,20 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,210 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| BEAM THERAPEUTICS | 21,280 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 16,930 | 0,00 % | Arcutis bei H.C. Wainwright: Strategisches Wachstum und Pipeline-Entwicklung | ||
| AVIDITY BIOSCIENCES | 40,190 | 0,00 % | Avidity Biosciences schließt Kapitalerhöhung über 690 Millionen US-Dollar ab | ||
| CG ONCOLOGY | 34,600 | 0,00 % | Hedge Fund and Insider Trading News: Ray Dalio, Warren Buffett, Bill Ackman, Dan Loeb, Arrowpoint Investment Partners, CG Oncology Inc (CGON), Tesla Inc (TSLA), and More | ||
| RAPPORT THERAPEUTICS | 24,730 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | ||
| TOURMALINE BIO | 47,650 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 6,930 | 0,00 % | Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa | DJ Novartis schließt Entwicklungs-Partnerschaft mit Monte Rosa
Von Adriano Marchese
DOW JONES--Novartis hat eine potenziell milliardenschwere Entwicklungspartnerschaft mit dem US-Biotechunternehmen... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,850 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,065 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,410 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report |
SHANDONG BOAN BIOTECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,520 Euro und damit +11,76 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANDONG BOAN BIOTECHNOLOGY CO LTD finden Sie auf Wallstreet Online.